An FDA panel gave San Diego-based Dexcom Inc. good news Thursday, voting 8 to 2 that the benefits of its G5 continuous glucose monitor to replace fingerstick testing for diabetes management outweigh the risks. Members voted similarly on the question of safety (8 to 2) and efficacy (9 to 1).